Long-term Study of Conservative Treatment in Moyamoya Disease Patients and Their Close Relatives

What this Trial Is About

Researchers are investigating the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives. Moyamoya disease is a chronic condition involving narrowing of arteries in the brain, caused by genetic, inflammatory, immunological, and environmental factors. The exact cause is still unclear, and understanding long-term effects of non-surgical treatments could provide insights into the diseases development. Participants will receive conservative medical treatment tailored to their symptoms, including antiplatelets, antiepileptics, antihypertensives, and vasodilators. The study includes both patients diagnosed with moyamoya disease and their first-degree relatives who may carry genetic variants. The research team will observe these groups over several years without surgical intervention to evaluate treatment outcomes. During the study, participants will be monitored with regular assessments at baseline and multiple follow-up points up to five years. These include cerebrovascular event tracking, neurological outcome evaluations, brain imaging using methods like CTP, CTA, MRA, and HR-MRI, and blood tests for biomarkers. The study aims to better understand disease progression and treatment effects over time, with ongoing follow-up to ensure comprehensive data collection.

Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)